| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHDERM.139.1.50 |
| P8608 | Fatcat ID | release_ps5sdivt3zdezev6d7wrb66khi |
| P698 | PubMed publication ID | 12533164 |
| P5875 | ResearchGate publication ID | 10946431 |
| P2093 | author name string | Alan B Fleischer | |
| Martha A McCarty | |||
| Tamara Salam Housman | |||
| Joseph L Jorizzo | |||
| Paul G Sutej | |||
| Sarah E Grummer | |||
| P433 | issue | 1 | |
| P921 | main subject | thalidomide | Q203174 |
| P304 | page(s) | 50-54 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Archives of Dermatology | Q15749524 |
| P1476 | title | Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus | |
| P478 | volume | 139 |
| Q64055010 | Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus |
| Q41945144 | Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients |
| Q90745219 | Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies |
| Q36365400 | Cutaneous lupus erythematosus: a personal approach to management |
| Q36134951 | Cutaneous manifestations of systemic lupus erythematosus. |
| Q35886371 | Diseases on hair follicles leading to hair loss part II: scarring alopecias |
| Q36907616 | Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus |
| Q86117481 | Genome-wide transcriptional profiling of chronic cutaneous lupus erythematosus (CCLE) peripheral blood identifies systemic alterations relevant to the skin manifestation |
| Q35097266 | Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial |
| Q38731966 | Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience |
| Q46613737 | Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients |
| Q46001895 | Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity. |
| Q33715138 | Lupus profundus limited to a site of trauma: Case report and review of the literature |
| Q37167668 | Management of primary cicatricial alopecias: options for treatment. |
| Q37754557 | Novel approaches to therapy for systemic lupus erythematosus: update 2005. |
| Q46864452 | Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus |
| Q52836583 | S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). |
| Q33238514 | Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells |
| Q35215252 | Thalidomide in dermatology: revisited |
| Q46835463 | Thalidomide in the treatment of chronic discoid lupus erythematosus |
| Q46374709 | Thalidomide treatment for hypertrophic cutaneous lupus erythematosus |
| Q47865124 | Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China. |
| Q44443369 | Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus? |
| Q36222128 | Thalidomide: dermatological indications, mechanisms of action and side-effects |
Search more.